Altimmune, Inc.
Altimmune, Inc. (ALT) Stock Competitors & Peer Comparison
See (ALT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALT | $2.82 | +8.46% | 248.9M | -2.82 | -$1.00 | N/A |
| VRTX | $423.92 | -0.81% | 107.8B | 27.67 | $15.32 | N/A |
| REGN | $701.42 | -0.80% | 72.9B | 17.13 | $40.94 | +0.51% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $783.50 | +0.23% | 48.5B | 39.95 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $296.11 | -4.32% | 39.5B | 74.17 | $3.99 | N/A |
| RVMD | $139.48 | -3.22% | 29.7B | -23.44 | -$5.95 | N/A |
| INSM | $133.26 | -2.25% | 28.8B | -20.76 | -$6.42 | N/A |
| UTHR | $570.40 | -0.17% | 25B | 20.48 | $27.85 | N/A |
Stock Comparison
ALT vs VRTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, VRTX has a market cap of 107.8B. Regarding current trading prices, ALT is priced at $2.82, while VRTX trades at $423.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas VRTX's P/E ratio is 27.67. In terms of profitability, ALT's ROE is -0.49%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check VRTX's competition here
ALT vs REGN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, REGN has a market cap of 72.9B. Regarding current trading prices, ALT is priced at $2.82, while REGN trades at $701.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas REGN's P/E ratio is 17.13. In terms of profitability, ALT's ROE is -0.49%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check REGN's competition here
ALT vs VRNA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALT is priced at $2.82, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALT's ROE is -0.49%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ALT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check VRNA's competition here
ALT vs ARGX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ARGX has a market cap of 48.5B. Regarding current trading prices, ALT is priced at $2.82, while ARGX trades at $783.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ARGX's P/E ratio is 39.95. In terms of profitability, ALT's ROE is -0.49%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ALT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ARGX's competition here
ALT vs SGEN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALT is priced at $2.82, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALT's ROE is -0.49%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check SGEN's competition here
ALT vs ALNY Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, ALT is priced at $2.82, while ALNY trades at $296.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ALNY's P/E ratio is 74.17. In terms of profitability, ALT's ROE is -0.49%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ALT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ALNY's competition here
ALT vs RVMD Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RVMD has a market cap of 29.7B. Regarding current trading prices, ALT is priced at $2.82, while RVMD trades at $139.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RVMD's P/E ratio is -23.44. In terms of profitability, ALT's ROE is -0.49%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ALT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RVMD's competition here
ALT vs INSM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, INSM has a market cap of 28.8B. Regarding current trading prices, ALT is priced at $2.82, while INSM trades at $133.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas INSM's P/E ratio is -20.76. In terms of profitability, ALT's ROE is -0.49%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ALT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check INSM's competition here
ALT vs UTHR Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, ALT is priced at $2.82, while UTHR trades at $570.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas UTHR's P/E ratio is 20.48. In terms of profitability, ALT's ROE is -0.49%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check UTHR's competition here
ALT vs BNTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BNTX has a market cap of 24.5B. Regarding current trading prices, ALT is priced at $2.82, while BNTX trades at $97.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BNTX's P/E ratio is -17.73. In terms of profitability, ALT's ROE is -0.49%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ALT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BNTX's competition here
ALT vs RPRX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RPRX has a market cap of 21.2B. Regarding current trading prices, ALT is priced at $2.82, while RPRX trades at $49.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RPRX's P/E ratio is 27.79. In terms of profitability, ALT's ROE is -0.49%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ALT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RPRX's competition here
ALT vs BGNE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALT is priced at $2.82, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALT's ROE is -0.49%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ALT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BGNE's competition here
ALT vs ROIV Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, ALT is priced at $2.82, while ROIV trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ROIV's P/E ratio is -23.79. In terms of profitability, ALT's ROE is -0.49%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ALT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ROIV's competition here
ALT vs INCY Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, ALT is priced at $2.82, while INCY trades at $96.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas INCY's P/E ratio is 13.69. In terms of profitability, ALT's ROE is -0.49%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ALT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check INCY's competition here
ALT vs DNA-WT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALT is priced at $2.82, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALT's ROE is -0.49%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ALT is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check DNA-WT's competition here
ALT vs MRNA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MRNA has a market cap of 18B. Regarding current trading prices, ALT is priced at $2.82, while MRNA trades at $45.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MRNA's P/E ratio is -6.25. In terms of profitability, ALT's ROE is -0.49%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ALT is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ALT.Check MRNA's competition here
ALT vs GMAB Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, GMAB has a market cap of 16.3B. Regarding current trading prices, ALT is priced at $2.82, while GMAB trades at $26.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas GMAB's P/E ratio is 17.18. In terms of profitability, ALT's ROE is -0.49%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ALT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check GMAB's competition here
ALT vs ASND Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ASND has a market cap of 13.6B. Regarding current trading prices, ALT is priced at $2.82, while ASND trades at $220.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ASND's P/E ratio is -50.21. In terms of profitability, ALT's ROE is -0.49%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ALT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ASND's competition here
ALT vs BBIO Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, ALT is priced at $2.82, while BBIO trades at $68.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BBIO's P/E ratio is -18.14. In terms of profitability, ALT's ROE is -0.49%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ALT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BBIO's competition here
ALT vs JAZZ Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, JAZZ has a market cap of 12.7B. Regarding current trading prices, ALT is priced at $2.82, while JAZZ trades at $202.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas JAZZ's P/E ratio is -34.76. In terms of profitability, ALT's ROE is -0.49%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ALT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check JAZZ's competition here
ALT vs KRTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALT is priced at $2.82, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALT's ROE is -0.49%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check KRTX's competition here
ALT vs SMMT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, SMMT has a market cap of 12.5B. Regarding current trading prices, ALT is priced at $2.82, while SMMT trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas SMMT's P/E ratio is -11.19. In terms of profitability, ALT's ROE is -0.49%, compared to SMMT's ROE of -2.91%. Regarding short-term risk, ALT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ALT.Check SMMT's competition here
ALT vs IONS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, ALT is priced at $2.82, while IONS trades at $75.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas IONS's P/E ratio is -37.45. In terms of profitability, ALT's ROE is -0.49%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ALT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check IONS's competition here
ALT vs MDGL Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, ALT is priced at $2.82, while MDGL trades at $513.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MDGL's P/E ratio is -39.92. In terms of profitability, ALT's ROE is -0.49%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ALT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MDGL's competition here
ALT vs RNAM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALT is priced at $2.82, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALT's ROE is -0.49%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RNAM's competition here
ALT vs EXEL Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, ALT is priced at $2.82, while EXEL trades at $43.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas EXEL's P/E ratio is 15.71. In terms of profitability, ALT's ROE is -0.49%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ALT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check EXEL's competition here
ALT vs AXSM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, ALT is priced at $2.82, while AXSM trades at $206.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas AXSM's P/E ratio is -56.12. In terms of profitability, ALT's ROE is -0.49%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ALT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check AXSM's competition here
ALT vs ARWR Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, ALT is priced at $2.82, while ARWR trades at $74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ARWR's P/E ratio is 46.76. In terms of profitability, ALT's ROE is -0.49%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ALT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ARWR's competition here
ALT vs BMRN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, ALT is priced at $2.82, while BMRN trades at $54.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BMRN's P/E ratio is 30.03. In terms of profitability, ALT's ROE is -0.49%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ALT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BMRN's competition here
ALT vs RXDX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALT is priced at $2.82, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALT's ROE is -0.49%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RXDX's competition here
ALT vs IMGN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALT is priced at $2.82, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALT's ROE is -0.49%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check IMGN's competition here
ALT vs TECH Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, ALT is priced at $2.82, while TECH trades at $55.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas TECH's P/E ratio is 103.85. In terms of profitability, ALT's ROE is -0.49%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ALT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check TECH's competition here
ALT vs BPMC Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALT is priced at $2.82, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALT's ROE is -0.49%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ALT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BPMC's competition here
ALT vs PCVX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, ALT is priced at $2.82, while PCVX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas PCVX's P/E ratio is -10.11. In terms of profitability, ALT's ROE is -0.49%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ALT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check PCVX's competition here
ALT vs CERE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALT is priced at $2.82, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALT's ROE is -0.49%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CERE's competition here
ALT vs KRYS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, KRYS has a market cap of 7.8B. Regarding current trading prices, ALT is priced at $2.82, while KRYS trades at $266.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas KRYS's P/E ratio is 38.88. In terms of profitability, ALT's ROE is -0.49%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check KRYS's competition here
ALT vs CYTK Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, ALT is priced at $2.82, while CYTK trades at $63.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CYTK's P/E ratio is -9.69. In terms of profitability, ALT's ROE is -0.49%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ALT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CYTK's competition here
ALT vs ABVX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, ALT is priced at $2.82, while ABVX trades at $117.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ABVX's P/E ratio is -20.78. In terms of profitability, ALT's ROE is -0.49%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ALT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ABVX's competition here
ALT vs HALO Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, ALT is priced at $2.82, while HALO trades at $63.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas HALO's P/E ratio is 24.99. In terms of profitability, ALT's ROE is -0.49%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ALT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check HALO's competition here
ALT vs MTSR Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALT is priced at $2.82, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALT's ROE is -0.49%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ALT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MTSR's competition here
ALT vs IBRX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, ALT is priced at $2.82, while IBRX trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas IBRX's P/E ratio is -18.71. In terms of profitability, ALT's ROE is -0.49%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ALT is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check IBRX's competition here
ALT vs NUVL Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, ALT is priced at $2.82, while NUVL trades at $99.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas NUVL's P/E ratio is -16.93. In terms of profitability, ALT's ROE is -0.49%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ALT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check NUVL's competition here
ALT vs PRAX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, ALT is priced at $2.82, while PRAX trades at $324.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas PRAX's P/E ratio is -24.03. In terms of profitability, ALT's ROE is -0.49%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ALT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check PRAX's competition here
ALT vs MRUS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALT is priced at $2.82, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALT's ROE is -0.49%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ALT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MRUS's competition here
ALT vs ACLX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALT is priced at $2.82, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALT's ROE is -0.49%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ACLX's competition here
ALT vs KYMR Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, KYMR has a market cap of 6.6B. Regarding current trading prices, ALT is priced at $2.82, while KYMR trades at $80.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas KYMR's P/E ratio is -22.53. In terms of profitability, ALT's ROE is -0.49%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ALT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check KYMR's competition here
ALT vs RETA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALT is priced at $2.82, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALT's ROE is -0.49%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RETA's competition here
ALT vs PTGX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, ALT is priced at $2.82, while PTGX trades at $98.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas PTGX's P/E ratio is -47.99. In terms of profitability, ALT's ROE is -0.49%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ALT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check PTGX's competition here
ALT vs BLTE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, ALT is priced at $2.82, while BLTE trades at $154.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BLTE's P/E ratio is -66.75. In terms of profitability, ALT's ROE is -0.49%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ALT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BLTE's competition here
ALT vs CELC Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CELC has a market cap of 6.1B. Regarding current trading prices, ALT is priced at $2.82, while CELC trades at $125.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CELC's P/E ratio is -33.15. In terms of profitability, ALT's ROE is -0.49%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ALT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CELC's competition here
ALT vs COGT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ALT is priced at $2.82, while COGT trades at $36.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas COGT's P/E ratio is -16.96. In terms of profitability, ALT's ROE is -0.49%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ALT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check COGT's competition here
ALT vs CNTA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, ALT is priced at $2.82, while CNTA trades at $39.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CNTA's P/E ratio is -27.10. In terms of profitability, ALT's ROE is -0.49%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, ALT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CNTA's competition here
ALT vs CDTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALT is priced at $2.82, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALT's ROE is -0.49%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ALT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CDTX's competition here
ALT vs CGON Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, ALT is priced at $2.82, while CGON trades at $66.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CGON's P/E ratio is -31.86. In terms of profitability, ALT's ROE is -0.49%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CGON's competition here
ALT vs RYTM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, ALT is priced at $2.82, while RYTM trades at $81.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RYTM's P/E ratio is -26.31. In terms of profitability, ALT's ROE is -0.49%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ALT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RYTM's competition here
ALT vs ALKS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, ALT is priced at $2.82, while ALKS trades at $33.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ALKS's P/E ratio is 23.34. In terms of profitability, ALT's ROE is -0.49%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ALT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ALKS's competition here
ALT vs ABCM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALT is priced at $2.82, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALT's ROE is -0.49%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ABCM's competition here
ALT vs CORT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, ALT is priced at $2.82, while CORT trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CORT's P/E ratio is 62.71. In terms of profitability, ALT's ROE is -0.49%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ALT is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ALT.Check CORT's competition here
ALT vs IMVT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, ALT is priced at $2.82, while IMVT trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas IMVT's P/E ratio is -10.16. In terms of profitability, ALT's ROE is -0.49%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ALT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check IMVT's competition here
ALT vs ISEE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALT is priced at $2.82, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALT's ROE is -0.49%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ISEE's competition here
ALT vs TGTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, ALT is priced at $2.82, while TGTX trades at $33.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas TGTX's P/E ratio is 12.21. In terms of profitability, ALT's ROE is -0.49%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ALT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check TGTX's competition here
ALT vs PTCT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, ALT is priced at $2.82, while PTCT trades at $65.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas PTCT's P/E ratio is 7.59. In terms of profitability, ALT's ROE is -0.49%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ALT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check PTCT's competition here
ALT vs SRRK Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, ALT is priced at $2.82, while SRRK trades at $46.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas SRRK's P/E ratio is -14.09. In terms of profitability, ALT's ROE is -0.49%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ALT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check SRRK's competition here
ALT vs APLS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, ALT is priced at $2.82, while APLS trades at $40.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas APLS's P/E ratio is 227.56. In terms of profitability, ALT's ROE is -0.49%, compared to APLS's ROE of +0.08%. Regarding short-term risk, ALT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check APLS's competition here
ALT vs CAI Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, ALT is priced at $2.82, while CAI trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CAI's P/E ratio is -5.74. In terms of profitability, ALT's ROE is -0.49%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ALT is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CAI's competition here
ALT vs FBIOX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ALT is priced at $2.82, while FBIOX trades at $24.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ALT's ROE is -0.49%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ALT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check FBIOX's competition here
ALT vs CRSP Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ALT is priced at $2.82, while CRSP trades at $51.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CRSP's P/E ratio is -7.98. In terms of profitability, ALT's ROE is -0.49%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ALT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CRSP's competition here
ALT vs MIRM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, ALT is priced at $2.82, while MIRM trades at $96.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MIRM's P/E ratio is -205.38. In terms of profitability, ALT's ROE is -0.49%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ALT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MIRM's competition here
ALT vs TERN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALT is priced at $2.82, while TERN trades at $52.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas TERN's P/E ratio is -51.39. In terms of profitability, ALT's ROE is -0.49%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check TERN's competition here
ALT vs FOLD Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALT is priced at $2.82, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALT's ROE is -0.49%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check FOLD's competition here
ALT vs LGND Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, ALT is priced at $2.82, while LGND trades at $227.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas LGND's P/E ratio is 37.10. In terms of profitability, ALT's ROE is -0.49%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ALT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check LGND's competition here
ALT vs APGE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, APGE has a market cap of 4.5B. Regarding current trading prices, ALT is priced at $2.82, while APGE trades at $80.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas APGE's P/E ratio is -19.13. In terms of profitability, ALT's ROE is -0.49%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ALT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check APGE's competition here
ALT vs AKRO Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALT is priced at $2.82, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALT's ROE is -0.49%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ALT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check AKRO's competition here
ALT vs ALPN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALT is priced at $2.82, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALT's ROE is -0.49%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ALPN's competition here
ALT vs XENE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, ALT is priced at $2.82, while XENE trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas XENE's P/E ratio is -12.87. In terms of profitability, ALT's ROE is -0.49%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ALT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check XENE's competition here
ALT vs LEGN Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, LEGN has a market cap of 4.4B. Regarding current trading prices, ALT is priced at $2.82, while LEGN trades at $23.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas LEGN's P/E ratio is -14.65. In terms of profitability, ALT's ROE is -0.49%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ALT is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check LEGN's competition here
ALT vs OPT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALT is priced at $2.82, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALT's ROE is -0.49%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ALT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check OPT's competition here
ALT vs SYRE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, ALT is priced at $2.82, while SYRE trades at $69.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas SYRE's P/E ratio is -35.06. In terms of profitability, ALT's ROE is -0.49%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, ALT is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check SYRE's competition here
ALT vs MRTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALT is priced at $2.82, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALT's ROE is -0.49%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MRTX's competition here
ALT vs KNSA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, KNSA has a market cap of 4.1B. Regarding current trading prices, ALT is priced at $2.82, while KNSA trades at $55.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas KNSA's P/E ratio is 60.74. In terms of profitability, ALT's ROE is -0.49%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ALT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check KNSA's competition here
ALT vs CRNX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, ALT is priced at $2.82, while CRNX trades at $39.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CRNX's P/E ratio is -7.88. In terms of profitability, ALT's ROE is -0.49%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ALT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CRNX's competition here
ALT vs TVTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, ALT is priced at $2.82, while TVTX trades at $44.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas TVTX's P/E ratio is -77.40. In terms of profitability, ALT's ROE is -0.49%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, ALT is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check TVTX's competition here
ALT vs TLX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, ALT is priced at $2.82, while TLX trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas TLX's P/E ratio is -563.00. In terms of profitability, ALT's ROE is -0.49%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ALT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check TLX's competition here
ALT vs MANE Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, MANE has a market cap of 3.8B. Regarding current trading prices, ALT is priced at $2.82, while MANE trades at $101.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas MANE's P/E ratio is -42.50. In terms of profitability, ALT's ROE is -0.49%, compared to MANE's ROE of -0.76%. Regarding short-term risk, ALT is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check MANE's competition here
ALT vs ACAD Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ALT is priced at $2.82, while ACAD trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ACAD's P/E ratio is 9.54. In terms of profitability, ALT's ROE is -0.49%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ALT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ACAD's competition here
ALT vs RYZB Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALT is priced at $2.82, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALT's ROE is -0.49%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check RYZB's competition here
ALT vs CBAY Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALT is priced at $2.82, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALT's ROE is -0.49%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CBAY's competition here
ALT vs SWTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALT is priced at $2.82, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALT's ROE is -0.49%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ALT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check SWTX's competition here
ALT vs CPRX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, CPRX has a market cap of 3.5B. Regarding current trading prices, ALT is priced at $2.82, while CPRX trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas CPRX's P/E ratio is 17.11. In terms of profitability, ALT's ROE is -0.49%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check CPRX's competition here
ALT vs VKTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, ALT is priced at $2.82, while VKTX trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas VKTX's P/E ratio is -7.23. In terms of profitability, ALT's ROE is -0.49%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ALT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check VKTX's competition here
ALT vs LQDA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, LQDA has a market cap of 3.4B. Regarding current trading prices, ALT is priced at $2.82, while LQDA trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas LQDA's P/E ratio is -47.69. In terms of profitability, ALT's ROE is -0.49%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ALT is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check LQDA's competition here
ALT vs DNTH Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, ALT is priced at $2.82, while DNTH trades at $87.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas DNTH's P/E ratio is -20.81. In terms of profitability, ALT's ROE is -0.49%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ALT is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check DNTH's competition here
ALT vs EWTX Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, EWTX has a market cap of 3.3B. Regarding current trading prices, ALT is priced at $2.82, while EWTX trades at $30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas EWTX's P/E ratio is -18.78. In terms of profitability, ALT's ROE is -0.49%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ALT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check EWTX's competition here
ALT vs NAMS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, ALT is priced at $2.82, while NAMS trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas NAMS's P/E ratio is -16.53. In terms of profitability, ALT's ROE is -0.49%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ALT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check NAMS's competition here
ALT vs KLRA Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, KLRA has a market cap of 3.3B. Regarding current trading prices, ALT is priced at $2.82, while KLRA trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas KLRA's P/E ratio is -19.94. In terms of profitability, ALT's ROE is -0.49%, compared to KLRA's ROE of N/A. Regarding short-term risk, ALT is more volatile compared to KLRA. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check KLRA's competition here
ALT vs BEAM Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, ALT is priced at $2.82, while BEAM trades at $30.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas BEAM's P/E ratio is -37.90. In terms of profitability, ALT's ROE is -0.49%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, ALT is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check BEAM's competition here
ALT vs ERAS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ERAS has a market cap of 3.1B. Regarding current trading prices, ALT is priced at $2.82, while ERAS trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ERAS's P/E ratio is -22.80. In terms of profitability, ALT's ROE is -0.49%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ALT is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ALT.Check ERAS's competition here
ALT vs ALMS Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, ALT is priced at $2.82, while ALMS trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ALMS's P/E ratio is -8.80. In terms of profitability, ALT's ROE is -0.49%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, ALT is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ALMS's competition here
ALT vs ARQT Comparison May 2026
ALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALT stands at 248.9M. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, ALT is priced at $2.82, while ARQT trades at $23.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALT currently has a P/E ratio of -2.82, whereas ARQT's P/E ratio is -179.62. In terms of profitability, ALT's ROE is -0.49%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, ALT is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for ALT.Check ARQT's competition here